Introduction: Pincus and his group's initial research on hormonal contraception focused on progesterone. However, the natural compound could not be utilized in clinical practice because of the high incidence of breakthrough bleeding and its low oral availability. This led to the introduction of orally-active progestins. The estrogen was added to ensure proper cycle control.
Areas covered: Concern about side effects of combined oral contraceptive pills (COC) and specifically the increased occurrence of thromboembolism was raised at the very early stages of clinical use. These were attributed to the estrogenic component, ethinyl estradiol (EE). The first pill scare followed the publication in 1977 of evidence of thromboembolism related mortality in COC users. This and subsequent alarming publications acted as the engine for a successful attempt to substantially decrease the daily content of EE in a COC. Over time, adverse events were also reported for the newer progestins compared to levonorgestrel.
Expert opinion: Attempts have been made to utilize natural estrogens in COC based on the assumption that this will reduce adverse effects. The wide range of progestins available for use in COC renders comparisons between preparations more challenging. Each progestin has its own androgenic, antiandrogenic, antiestrogenic and mineralocorticoid activity and, consequently, a unique risk and benefit profile.
Keywords: Hormonal contraception; adverse effects; contraceptive pill; estrogens; ethinyl estradiol; pill scare; progestins; venous thromboembolism.
Thestarting point in the search for hormonal contraception was theobservation that the ovaries do not release eggs (ovulation) duringpregnancy because of the high levels of the hormone progesterone.Early clinical trials found that progesterone was not absorbed whentaken by mouth (orally) and resulted in irregular bleeding. For thesereasons, it was substituted with synthetic versions that could betaken orally.Researcherssoon recognized the need to add small amounts of an estrogen, leadingto the development of the ‘combined pill.’ This containedmodified molecules that worked similarly to the natural substances,estradiol (a form of estrogen) and progesterone.Inresponse to clinical observations and population-based studies thatreported on side effects, the amount of estrogen was graduallyreduced, and newer progesterone-like compounds were introduced.Thedevelopment journey was a stormy one as it featured ‘pill scares’where medical literature and news media published alarming headlinesabout increased risks or mortality. Some of these scares resulted inmore unwanted pregnancies and abortions as women abandoned the pill.Newer pills are now available but, as for all medications, have bothbenefits and side-effects. The critical consideration is weighing thelarge benefit against the small risk.